1
|
Hosseini Toudeshki S, Garousi M, Arefpour AM, Fadavi P, Basi A, Foroughi A, Javadinia SA. Outcomes of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone in Esophageal Squamous Cell Carcinoma Induction chemotherapy in Esophageal Squamous Cell Carcinoma. Asian Pac J Cancer Prev 2024; 25:1183-1188. [PMID: 38679976 DOI: 10.31557/apjcp.2024.25.4.1183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Indexed: 05/01/2024] Open
Abstract
BACKGROUND There is still no definite conclusion regarding the effect of Induction Chemotherapy (IC) combined with concurrent Chemoradiotherapy (CRT). Thus this study was aimed to assess outcomes of IC followed By CRT versus CRT alone in Esophageal Squamous Cell Carcinoma (ESCC). METHODS This multicenter retrospective study performed on 105 patients who underwent CRT and 73 patients who underwent IC+CRT, between January 2016 and December 2018. The primary endpoints were OS (from the date of treatment to the date of death or 3- years follow-Up). The toxicities of CRT were graded according to the National Cancer Institute Common Toxicity Criteria (version 3.0). RESULTS one-year (73.8% vs. 53.2%) and 2-year (53.4% vs. 38.5%) OS rate of the IC+CRT group was significantly higher than that of the CRT group (p < 0.05). No statistically significant differences were observed between the IC+CRT group and the CRT group (31.5% vs. 27.4%) in terms of the 3-year OS rate (p > 0.05). In multivariate logistic regression, age<60 (OR: 1.48; CI 95% 1.02-1.97), clinical staging II (OR: 1.36; CI 95% 1.11-1.88), and the addition of IC (OR: 1.66; CI 95% 1.07-2.19) were independent prognostic factors that affected survival positively. CONCLUSION Our data demonstrated that a combination of IC and CRT might be a promising treatment strategy to further improve OS in ESCC patients.
Collapse
Affiliation(s)
| | - Maryam Garousi
- Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
| | | | - Pedram Fadavi
- Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
| | - Ali Basi
- Department of Hematology and Oncology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Ahmad Foroughi
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Seyed Alireza Javadinia
- Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
| |
Collapse
|
2
|
Behnam B, Fazilaty H, Ghadyani M, Fadavi P, Taghizadeh-Hesary F. Ciliated, Mitochondria-Rich Postmitotic Cells are Immune-privileged, and Mimic Immunosuppressive Microenvironment of Tumor-Initiating Stem Cells: From Molecular Anatomy to Molecular Pathway. FRONT BIOSCI-LANDMRK 2023; 28:261. [PMID: 37919090 DOI: 10.31083/j.fbl2810261] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 09/15/2023] [Accepted: 10/09/2023] [Indexed: 11/04/2023]
Abstract
Cancer whose major problems are metastasis, treatment resistance, and recurrence is the leading cause of death worldwide. Tumor-initiating stem cells (TiSCs) are a subset of the tumor population responsible for tumor resistance and relapse. Understanding the characteristics and shared features between tumor-initiating stem cells (TiSCs) and long-lived postmitotic cells may hold a key to better understanding the biology of cancer. Postmitotic cells have exited the cell cycle and are transitioned into a non-dividing and terminally differentiated state with a specialized function within a tissue. Conversely, a cancer cell with TiSC feature can divide and produce a variety of progenies, and is responsible for disease progression, tumor resistance to therapy and immune system and disease relapse. Surprisingly, our comprehensive evaluation of TiSCs suggests common features with long-lived post-mitotic cells. They are similar in structure (primary cilia, high mitochondrial content, and being protected by a barrier), metabolism (autophagy and senescence), and function (immunoescape and/or immune-privileged by a blood barrier). In-depth exploration showed how mitochondrial metabolism contributes to these shared features, including high energy demands arising from ciliary and microtubular functionality, increased metabolic activity, and movement. These findings can assist in decoding the remaining properties which offer insights into the biology of TiSCs, with potential implications for enhancing cancer treatment strategies and patient prognosis.
Collapse
Affiliation(s)
- Babak Behnam
- Department of Regulatory Affairs, Amarex Clinical Research, NSF International, Germantown, MD 20874, USA
| | - Hassan Fazilaty
- Department of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland
| | - Mobina Ghadyani
- School of Science, Monash University, Melbourne, VIC 3800, Australia
| | - Pedram Fadavi
- Department of Radiation Oncology, Iran University of Medical Sciences, 1445613131 Tehran, Iran
| | - Farzad Taghizadeh-Hesary
- Department of Radiation Oncology, Iran University of Medical Sciences, 1445613131 Tehran, Iran
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, 1445613131 Tehran, Iran
| |
Collapse
|
3
|
Fadavi P, Garousi M, Soltani S, Montazer F, Abolhasani M, Asgari S, Mirzaee E. The uterine adenosarcoma with postoperative residual in a woman treated by total abdominal hysterectomy/bilateral salpingo-oophorectomy: A case report and review of literature. Cancer Rep (Hoboken) 2023; 6:e1891. [PMID: 37592402 PMCID: PMC10598255 DOI: 10.1002/cnr2.1891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 07/09/2023] [Accepted: 07/22/2023] [Indexed: 08/19/2023] Open
Abstract
BACKGROUND In patients with uterine adenosarcoma, a total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) is typically recommended as an initial treatment. There is no consensus on adjuvant therapies. CASE We report the case of a patient with uterine adenosarcoma with postoperative residual disease. We performed four courses of adjuvant chemotherapy, including Ifosfamide, Mesna, and Adriamycin, and whole pelvic radiation with a dose of 50.4 Gy/28 Fr. CONCLUSION A combination of chemotherapy and radiotherapy may be a promising treatment option for uterine adenosarcoma with postoperative residual disease.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, School of MedicineIran University of Medical SciencesTehranIran
| | - Maryam Garousi
- Department of Radiation Oncology, School of MedicineIran University of Medical SciencesTehranIran
| | - Sepideh Soltani
- Department of Radiation Oncology, School of MedicineIran University of Medical SciencesTehranIran
| | - Fatemeh Montazer
- Department of Pathology, School of MedicineIran University of Medical SciencesTehranIran
| | - Maryam Abolhasani
- Oncopathology Research Center, School of MedicineIran University of Medical SciencesTehranIran
| | - Salar Asgari
- Department of Pathology, School of MedicineIran University of Medical SciencesTehranIran
| | - Elahe Mirzaee
- Department of Radiation Oncology, School of MedicineIran University of Medical SciencesTehranIran
| |
Collapse
|
4
|
Garousi M, Hariri R, Fadavi P, Yousefi T, Bayani R. Dramatic response to radiation of a sinus melanoma: A case report. Clin Case Rep 2023; 11:e7037. [PMID: 36873064 PMCID: PMC9981578 DOI: 10.1002/ccr3.7037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 08/09/2022] [Accepted: 10/07/2022] [Indexed: 03/06/2023] Open
Abstract
In this report, we shared our experience in the treatment of a patient with unresectable sinonasal melanoma, in whom a complete radiographic response was seen after a course of conventional external beam radiotherapy. Given that local control has an important role in maintaining the quality of life of patients.
Collapse
Affiliation(s)
- Maryam Garousi
- Department of Radiation Oncology, School of Medicine Iran University of Medical Sciences Tehran Iran
| | - Ramyar Hariri
- Department of Radiation Oncology, School of Medicine Iran University of Medical Sciences Tehran Iran
| | - Pedram Fadavi
- Department of Radiation Oncology, School of Medicine Iran University of Medical Sciences Tehran Iran
| | - Tahere Yousefi
- Department of anatomical pathology, Amir Alam Hospital Tehran University of medical sciences Tehran Iran
| | - Reyhaneh Bayani
- Radiation oncology department Hamadan university of medical sciences Hamadan Iran
| |
Collapse
|
5
|
Shahbazi-Gahrouei D, Bagherzadeh S, Torabinezhad F, Mahdavi SM, Fadavi P, Salmanian S. Binary logistic regression modeling of voice impairment and voice assessment in iranian patients with nonlaryngeal head-and-neck cancers after chemoradiation therapy: Objective and subjective voice evaluation. J Med Signals Sens 2023. [DOI: 10.4103/jmss.jmss_143_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
6
|
Novin K, Fadavi P, Mortazavi N, Sanei M, Khoshbakht Ahmadi H, Barahman M, Noori R, Hoveidamanesh S, Shahin M, Taghizadeh-Hesary F. Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study. Asian Pac J Cancer Prev 2023; 24:61-67. [PMID: 36708552 PMCID: PMC10152857 DOI: 10.31557/apjcp.2023.24.1.61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND The literature is inconsistent for the role of neutrophil-to-lymphocyte ratio (NLR) obtained before neoadjuvant therapy (pre-NLR) in predicting pathological response to neoadjuvant chemoradiation (neoCRT) in patients with locally advanced rectal cancer (LARC). In the present cohort study, we explored the predictive role of pre-NLR in this setting. METHODS We prospectively included patients with LARC who were candidates for neoCRT at the Shohada-e-Hafte Tir Hospital (Tehran, Iran) between Mar 2018 and Feb 2020. The pre-NLR was obtained through a peripheral blood smear before CRT. We used the AJCC system for evaluating tumor regression grade (TRG). The TRGs were categorized into: response-group 1 (TRG 0-1 vs. 2-3), response-group 2 (TRG 0 vs. 1-3), and response-group 3 (TRG 0-2 vs. 3). We applied receiver operating characteristic (ROC) analysis to assess the predictive value of pre-NLR. RESULTS Of the 86 screened patients with rectal cancer, 30 patients who fulfilled the inclusion criteria were included in the study. In total, 63.3% were responsive, and 23.3% had complete pathologic response. Pre-NLR could not predict the pathologic response in response-group 1 (area under the ROC curve [AUC]: 0.45, 95%CI 0.23-0.66) and response-group 2 (AUC: 0.36, 95%CI 0.13-0.59). Nevertheless, it had a poor predictive value in response-group 3 (AUC: 0.55, CI%95 0.33-0.75) with an optimal NLR cutoff value of 2.94. CONCLUSIONS Pre-NLR could not predict the pathological response to neoCRT in our cohort of patients with LARC.
Collapse
Affiliation(s)
- Kambiz Novin
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran
| | - Pedram Fadavi
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran
| | - Nafiseh Mortazavi
- Department of Pathology, Iran University of Medical science, Tehran, Iran
| | - Mastaneh Sanei
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran
| | | | - Maedeh Barahman
- Firoozgar Clinical Research Development Center(FCRDC), Iran University of Medical Science, Tehran, Iran
| | - Reyhaneh Noori
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran
| | | | - Mohadeseh Shahin
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran
| | - Farzad Taghizadeh-Hesary
- Department of Radiation Oncology, Iran University of Medical Science, Tehran, Iran.,ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
7
|
Haghpanah M, Azimi A, Fadavi P, Bagheri SM, Arefpour AM. The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report. Cureus 2022; 14:e29680. [PMID: 36321052 PMCID: PMC9615099 DOI: 10.7759/cureus.29680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/27/2022] [Indexed: 11/26/2022] Open
Abstract
Metastatic renal cell carcinoma (RCC) is a therapeutic challenge to clinicians since it shows significant resistance to chemotherapy and radiation therapy. With the introduction of immunotherapy, the treatment paradigm for RCC has evolved. Here, we describe the case of a 55-year-old male who presented with flank pain. An abdominal-pelvic computed tomography (CT) scan revealed a right renal mass. Following open right radical nephrectomy, first-line treatment with sunitinib was administered. After four months he developed multiple metastases to the liver, lungs, abdominal wall, and brain. He initiated second-line treatment with nivolumab and also received whole brain radiation therapy (WBRT). Six months following combined treatment with nivolumab and WBRT, a CT scan revealed complete radiologic response in the lungs, abdominal wall, brain, and liver except for the persistence of a subhepatic mass. Despite the discontinuation of nivolumab and starting bevacizumab due to financial problems, the patient was stable for 22 months, and after this, he was hospitalized with high bilirubin levels. An abdominal CT scan detected the development of the necrotic subhepatic mass compressing the common bile duct (CBD), with no other sign of metastatic disease. We believe that the explanation for this long-term disease control could be the combination of immune-checkpoint-inhibitor (ICI) with WBRT resulting in significant cranial and extracranial immune response, known as "the abscopal effect". This report highlights the importance of local therapy combined with ICI-based therapy in metastatic RCC.
Collapse
|
8
|
Abstract
Eosinophilic angiocentric fibrosis (EAF) is a rare progressive fibrosing lesion involving the nasal cavity, paranasal sinuses, and the upper respiratory tract. There are few reports that it rarely involves the orbit; however, there is no report of intracranial involvement. Here, we report and share our experience with a rare case of primary intracranial EAF. A 33-year-old woman with a history of a suprasellar mass and unsuccessful surgical and medical treatment referred to us. Physical examination demonstrated right-sided blindness and ptosis, left-sided decreased visual acuity, and visual field defect. The brain imaging revealed an extra-axial intradural well-defined large suprasellar mass with parasellar (more on the right side) and retrosellar extension. Via pterional craniotomy and subfrontal approach, a very firm creamy-brownish well-defined fibrotic mass was encountered. The tumour texture was too firm to be totally resected. The microscope exited the surgical field off, and the tumour was incompletely resected using a rongeur. The histopathology finding favoured EAF. Further histopathology evaluation failed to show histologic features of IgG4-related disease. Although the preoperative diagnosis of EAF is impossible, in the setting of an indolent slow-growing lesion demonstrating hypointensity on the T2 image sequence of MRI (magnetic resonance imaging), EAF should be considered a differential diagnosis. In the setting of this diagnosis, the systemic and other organ involvement for a diagnosis of IgG4-RD should be evaluated. However, more cases are needed to illustrate the relation between these two entities.
Collapse
Affiliation(s)
- Seyed Abdolhadi Daneshi
- Department of Neurosurgery, Iran University of Medical Sciences, 7Tir Hospital, Tehran, Iran
| | - Morteza Taheri
- Department of Neurosurgery, Iran University of Medical Sciences, 7Tir Hospital, Tehran, Iran.
| | - Arash Fattahi
- Department of Neurosurgery, Iran University of Medical Sciences, 7Tir Hospital, Tehran, Iran
| | - Pedram Fadavi
- Department of Radiotherapy, Iran University of Medical Sciences, 7Tir Hospital, Tehran, Iran
| |
Collapse
|
9
|
Fadavi P, Mehrabian A, Salmanian S, Mahdavi SR, Yousefi Diba AA, Javadinia SA. The Relationship between Lung and Heart Two-Dimensional Parameters and Three-Dimensional Dose-Volume Data in Adjuvant Radiotherapy for Breast Cancer. Med J Islam Repub Iran 2022; 36:16. [PMID: 35999926 PMCID: PMC9386768 DOI: 10.47176/mjiri.36.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 03/02/2022] [Indexed: 11/09/2022] Open
Abstract
Background: Two-dimensional (2D) radiographic parameters have been used to estimate the amount of heart and lung irradiated for minimizing heart and lung complications in breast cancer patients. The aim of this study was to investigate the correlation between traditionally used 2D radiographic and dose-volume parameters during adjuvant radiotherapy of breast cancer.
Methods: In this cross-sectional study, we analyzed 121 female patients treated with breast-conserving surgery (BCS) or modified radical mastectomy (MRM) and 3D conformal radiotherapy (3DCRT) using two-field radiotherapy (2FRT) or three-field radiotherapy (3FRT) technique. All patients underwent computed tomography (CT)-planning. Two-D parameters, including central lung distance (CLD), maximum lung depth (MLD), maximum heart length (MHL), maximum heart distance (MHD), and chest wall separation (CWS), were measured using digitally reconstructed radiographs (DRR) and CT images. DVHs for lung, heart, and target were created. The Pearson correlation test was used to evaluate the correlation between 2D radiographic and dose-volume parameters.
Results: There was a correlation between CLD and ipsilateral lung V5-20Gy and Dmean and between MLD and ipsilateral lung V5-20Gy. In 2FRT, only moderate correlation between CLD and ipsilateral lung V20Gy (r = 0.453, P = 0.003) and between MLD and ipsilateral lung V20Gy (r = 0.593, P <0.001) were observed. Poor correlation of MHL and heart V25Gy (r = 0.409, P = 0.007) was seen only in 3FRT. There was a correlation between MHD and heart dose-volume data, with a strong correlation between MHD and heart V5-25Gy and Dmean (r = 0.875-0.934, P<0.001) in the 2FRT group. No correlation between CWS and breast Dmax was found. Conclusion: There was a correlation between 2D parameters (i.e., CLD, MLD, and MHD) and the heart and lung dose-volume parameters during adjuvant breast radiotherapy. Although CLD was correlated to ipsilateral lung V5-20Gy and Dmean, the correlation between CLD and ipsilateral lung V20Gy was greater than other dose-volume parameters. MHD provided a close estimation of heart dose-volume parameters.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Arezoo Mehrabian
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
- Corresponding author: Dr Arezoo Mehrabian,
| | - Soraya Salmanian
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Seied Rabi Mahdavi
- Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
- Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Ali Asghar Yousefi Diba
- Department of Radiotherapy, Cancer and Radiation Oncology Research Center, Shohadaye Hafte-Tir Hospital, Tehran, Iran
| | - Seyed Alireza Javadinia
- Cellular and Molecular Research Center, Sabzevar University of Medical Science, Sabzevar, Iran
| |
Collapse
|
10
|
Cheraghi A, Barahman M, Hariri R, Nikoofar A, Fadavi P. Comparison of the Pathological Response and Adverse Effects of Oxaliplatin and Capecitabine versus Paclitaxel and Carboplatin in the Neoadjuvant Chemoradiotherapy Treatment Approach for Esophageal and Gastroesophageal Junction Cancer: A Randomized Control Trial Study. Med J Islam Repub Iran 2021; 35:140. [PMID: 35321371 PMCID: PMC8842142 DOI: 10.47176/mjiri.35.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Indexed: 11/09/2022] Open
Affiliation(s)
- Aida Cheraghi
- Department of Radiotherapy, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Maedeh Barahman
- Department of Radiotherapy, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Ramyar Hariri
- Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Alireza Nikoofar
- Department of Radiotherapy, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
- Corresponding author: Dr Alireza Nikoofar,
| | - Pedram Fadavi
- Department of Radiotherapy, Shohaday-e-Haftom-e-Tir Hospital, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
11
|
Fadavi P, Nafisi N, Hariri R, Novin K, Sanei M, Razzaghi Z, Arefpour A, Garousi M. Serum Ferritin, Vitamin D and Pathological Factors in Breast Cancer Patients. Med J Islam Repub Iran 2021; 35:162. [PMID: 35465166 PMCID: PMC8985634 DOI: 10.47176/mjiri.35.162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Indexed: 12/02/2022] Open
Abstract
Background:
Breast cancer is one of the most common cancers. Researchers are trying to diagnose the disease through easier and safer methods. Serum markers such as ferritin and vitamin D level would be very helpful. This research could pave the way for more comprehensive studies on how to use this serum factor in breast cancer screening, as well as early detection of the disease in its early stages. Methods:
This study consisted of two groups, the first group comprising patients diagnosed with breast cancer before undergoing any treatment and the second group as control were healthy people. Serum ferritin and vitamin D levels were measured. Pathological information of the patient's tumor, including ER, HER2, KI67, lymphovascular invasion, and disease stage, were collected as well. Data were analyzed by IBM SPSS advanced statistics version 23.0 (SPSS Inc., Chicago, IL). P-value of ≤0.05 was considered significant. Results:
Eighty-eight subjects were enrolled in this study, 29 (33%) breast cancer patients and 59 (67%) healthy women. In breast cancer patients, serum ferritin levels were 106.55±111.25, which were higher than healthy women’s serum ferritin 52.71±36.95 (p=0.083). Furthermore, 18 (66.7%) of breast cancer patients and 55 (93.2%) of healthy women had low serum ferritin levels (p=0.001). 3 (11.1%) patients in the cancer group had serum vitamin D deficiency, while all subjects in the control group had serum vitamin D higher than 10 ng/dl (p =0.009). Conclusion:
The results of this study showed a correlation between breast cancer and vitamin D deficiency, and elevated ferritin. Perhaps with further studies, there could be a role in predicting the prognosis and screening of breast cancer for these associations.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Nahid Nafisi
- Department of General Surgery, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Ramyar Hariri
- Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Kambiz Novin
- Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mastaneh Sanei
- Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Zahra Razzaghi
- Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Amirmohammad Arefpour
- Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Maryam Garousi
- Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
- Corresponding author:Maryam Garousi,Dr Maryam Garousi,
| |
Collapse
|
12
|
Fadavi P, Arefpour AM, Hariri R, Vasheghani M, Garousi M, Taghizadeh‐Hesary F. Dramatic response of aneurysmal bone cyst to denosumab: Case report and literature review. Clin Case Rep 2021; 9:e04993. [PMID: 34745616 PMCID: PMC8548816 DOI: 10.1002/ccr3.4993] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/12/2021] [Accepted: 10/09/2021] [Indexed: 02/02/2023] Open
Abstract
Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor-kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.
Collapse
Affiliation(s)
- Pedram Fadavi
- Radiation Oncology DepartmentIran University of Medical ScienceTehranIran
| | | | - Ramyar Hariri
- Radiation Oncology DepartmentIran University of Medical ScienceTehranIran
| | - Maryam Vasheghani
- Radiation Oncology DepartmentIran University of Medical ScienceTehranIran
| | - Maryam Garousi
- Radiation Oncology DepartmentIran University of Medical ScienceTehranIran
| | | |
Collapse
|
13
|
Arefpour AM, Abbasi M, Rabi Mahdavi S, Shafieesabet M, Fadavi P. Clinical effects of rectal retractor application in prostate cancer radiotherapy. Med J Islam Repub Iran 2021; 35:69. [PMID: 34277506 PMCID: PMC8278024 DOI: 10.47176/mjiri.35.69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Indexed: 11/09/2022] Open
Abstract
Background: Radiation-induced rectal toxicities remain as a major risk during prostate radiotherapy. One approach to the reduction of rectal radiation dose is to physically increase the distance between the rectal wall and prostate. Therefore, the aim of this study was to evaluate whether the application of the rectal retractor (RR) can reduce rectal dose and toxicity in prostate cancer 3-dimensional conformal radiotherapy (3D-CRT).
Methods: Overall, 36 patients with localized prostate cancer were randomized into the 2 groups, 18 patients with RR in-place and 18 without RR. All patients underwent planning computed tomography (CT). Patients were treated with 70 Gy in 35 fractions of 3D-CRT. In the RR group, RR was used during cone-down 20 treatment fractions. Acute and late gastrointestinal (GI) toxicities were assessed using EORTC/RTOG scoring system weekly during radiotherapy, 3, and 12 months after treatment. Device-related events were recorded according to CTCAE version 4.0. Patient characteristics, cancer differences, and dosimetric data for the RR and non-RR groups were compared using a Man-Whitney U test for continuous variables, and Fisher exact test for categorical data. The EORTC/RTOG scores for the 2 groups were compared using Fisher exact test. A P value <0.05 was considered statistically significant.
Results: A RR significantly reduced mean dose (Dmean) to the rectum as well as rectal volume receiving 50% to 95% (V50-95%) of prescribed dose. The absolute reduction of rectal Dmean was 10.3 Gy. There was no statistically significant difference in acute GI toxicity between groups during treatment or at 3 months. At 12 months, 2 patients in the RR group and 9 in the control group experienced late grade ≥ 1 GI toxicity (p=0.027). No patients in the RR group reported late grade ≥ 2 GI toxicity, whereas 3 patients in the control group experienced late grade 2 GI toxicity. In the RR group, 6 patients reported grade 1 rectal discomfort and pain according to CTCAE version 4.0.
Conclusion: The application of the RR showed a significant rectum sparing effect, resulting in substantially reducing late GI toxicity.
Collapse
Affiliation(s)
- Amir Mohammad Arefpour
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mahshid Abbasi
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Seied Rabi Mahdavi
- Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.,Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Mahdiyeh Shafieesabet
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Pedram Fadavi
- Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
14
|
Fadavi P, Nafissi N, Mahdavi SR, Jafarnejadi B, Javadinia SA. Outcome of hypofractionated breast irradiation and intraoperative electron boost in early breast cancer: A randomized non-inferiority clinical trial. Cancer Rep (Hoboken) 2021; 4:e1376. [PMID: 33797199 PMCID: PMC8552001 DOI: 10.1002/cnr2.1376] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 02/03/2021] [Accepted: 03/03/2021] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Intraoperative electron radiotherapy (IOERT) followed by hypofractionated whole breast irradiation (HWBI) provides the shortest possible time of adjuvant breast irradiation. The efficacy of either method has been described in previous reports; however, to our knowledge, the efficacy of combined therapy has not been reported. AIM To compare the toxicity and cosmetic outcome of IOERT as a tumor bed boost followed by HWBI with conventional whole breast irradiation (CWBI) followed by external electron tumor bed boost (EETBB) after breast conserving surgery (BCS) in patients with invasive breast cancer. METHODS In 2019, a prospective noninferiority trial (IRCT20180919041070N2) was started. After BCS, early-stage breast cancer patients were treated by IOERT (10 Gy) and HWBI (42.56 Gy in 16 fractions) or CWBI (50 Gy in 25 fraction) and EETBB (10 Gy in 5) in a double-arm design. Acute/late toxicity and cosmetic outcome were evaluated by common toxicity criteria (CTC) after 1-year follow-up (FUP) at the level of p < .05. RESULTS Of 60 eligible patients, 30 were allocated to each group. Regarding acute effects after a median FUP of 12 months, CTC-score of grade II-III erythema (p = .001) and desquamation (p = .005) were significantly higher in CWBI+EETBB compared to IOERT+ HWBI. However, there were no significant differences at the end of radiotherapy and after 1 month, 6 months, and 1 year. Cosmetic outcome after radiation was similar in both groups mostly rating as good/excellent after 1-year FUP. CONCLUSIONS Boost-IOERT/HWBI regimen has comparable acute and late treatment toxicity profiles compared to the CWBI.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
| | - Nahid Nafissi
- Department of General Surgery, Iran University of Medical Sciences, Tehran, Iran
| | - Seied Rabi Mahdavi
- Department of Medical Physics, Iran University of Medical Sciences, Tehran, Iran
| | - Bahareh Jafarnejadi
- Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
| | - Seyed Alireza Javadinia
- Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
| |
Collapse
|
15
|
Fadavi P, Houshyari M, Yousefi Kashi AS, Jarrahi AM, Roshanmehr F, Broomand MA, Sandoughdaran S, Taghizadeh-Hesary F. Review on the Oncology Practice in the Midst of COVID-19 Crisis: The Challenges and Solutions. Asian Pac J Cancer Prev 2021; 22:19-24. [PMID: 33507674 PMCID: PMC8184167 DOI: 10.31557/apjcp.2021.22.1.19] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Indexed: 11/25/2022] Open
Abstract
As of late 2019, the outbreak of novel coronavirus disease (COVID-19) –that started in China– has rapidly afflicted all over the world. The COVID-19 pandemic has challenged health-care facilities to provide optimal care. In this context, cancer care requires special attention because of its peculiar status by including patients who are commonly immunocompromised and treatments that are often highly toxic. In this review article, we have classified the main impacts of the COVID-19 pandemic on oncology practices –followed by their solutions– into ten categories, including impacts on (1) health care providers, (2) medical equipment, (3) access to medications, (4) treatment approaches, (5) patients’ referral, (6) patients’ accommodation, (7) patients’ psychological health, (8) cancer research, (9) tumor board meetings, and (10) economic income of cancer centers. The effective identification and management of all these challenges will improve the standards of cancer care over the viral pandemic and can be a practical paradigm for possible future crises.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
| | - Mohammad Houshyari
- Department of Clinical Oncology, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Amir Shahram Yousefi Kashi
- Department of Clinical Oncology, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Cancer Research Center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Alireza Mosavi Jarrahi
- Cancer Research Center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Farnaz Roshanmehr
- Faculty of Science and Engineering, Waseda University, Tokyo, Japan.,Kagawa Nutrition University, Saitama, Japan
| | - Mohammad Ali Broomand
- Department of Clinical Oncology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | - Saleh Sandoughdaran
- Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | |
Collapse
|
16
|
Fadavi P, Ahmadi HK, Diba AAY, Jafari F, Alamolhoda M. Dosimetric comparison of left sided whole breast irradiation with Tangential wedge beam, electron boosted Tangential wedged beam and asymmetric technique. J Family Med Prim Care 2020; 9:6135-6139. [PMID: 33681053 PMCID: PMC7928138 DOI: 10.4103/jfmpc.jfmpc_1476_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2020] [Revised: 09/15/2020] [Accepted: 11/03/2020] [Indexed: 11/05/2022] Open
Abstract
Background: Irradiation of the adjacent critical structures is inevitable in breast cancer radiotherapy (RT). Our purpose is to assess the dose distribution across the breast tissue and adjacent organs with our institutional asymmetric technique for left-sided breast cancer compared to the standard tangential wedged beam (TWB) and electron-boosted TWB techniques. Materials and Methods: The three RT planning were created for 30 consecutive patients with a focus on proper coverage of the planning target volume (PTV). The irritated doses into the heart, ipsilateral lung, and left anterior descending artery (LAD) were evaluated. Results: No significant difference was found in the mean values of relative PTV irradiated to 47.5 Gy, PTV dose and the volume of PTV, and critical organs between the treatments. The mean dose (Dmean) irradiated to the heart and LAD was lowest with the electron-boosted TWB. The Dmean to the heart was comparable between the TWB and asymmetric RT techniques, while the Dmean to LAD was significantly reduced with asymmetric technique versus TWB. The heart volume receiving ≥25 Gy and the Dmean to the left lung were significantly decreased with the asymmetric technique compared with TWB. The mean relative lung volume irradiated to ≥20 Gy was comparable between all techniques. The mean central lung distance was also significantly increased from 18.03 ± 4.5 cm with asymmetric RT to 37.47 ± 5.6 cm with TWB and to 27.67 ± 3.8 cm with electron-boosted TWB techniques. Conclusion: The asymmetric technique is useful for patients with breast cancer on the left side, having acceptable PTV coverage and considerably reduced cardiopulmonary doses.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, Shohadaye 7 Tir Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Helaleh Khoshbakht Ahmadi
- Department of Radiation Oncology, Shohadaye 7 Tir Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Ali Asghar Yousefi Diba
- Department of Radiation Oncology, Shohadaye 7 Tir Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Jafari
- Radiation Oncology Research Center, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.,Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahboobeh Alamolhoda
- Department of Radiation Oncology, Shohadaye 7 Tir Hospital, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
17
|
Ariyafar T, Mahdavi SR, Geraily G, Fadavi P, Farhood B, Najafi M, Ashouri A, Khalafi L, Shirazi A. Evaluating the effectiveness of combined radiotherapy and hyperthermia for the treatment response of patients with painful bony metastases: A phase 2 clinical trial. J Therm Biol 2019; 84:129-135. [PMID: 31466745 DOI: 10.1016/j.jtherbio.2019.06.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Revised: 03/27/2019] [Accepted: 06/01/2019] [Indexed: 01/03/2023]
Abstract
INTRODUCTION Since the survival time of patients with bony metastases has noticeably improved in recent years, these patients are at high risk of complications associated with this metastasis. Hence, the appropriate choice of treatment modality or combination of therapeutic approaches can lead to increasing bone pain relief, improving quality of life, etc. This study is aimed to evaluate the effectiveness of combined radiotherapy and hyperthermia for the treatment response of patients with painful bony metastases. PATIENTS AND METHODS In a single-arm clinical trial, 23 eligible patients (14 female and 9 male) with the mean age of 67 years old and suffering from bony metastases were enrolled in the study. Two hours after radiotherapy, the patients underwent hyperthermia for 1 h in the supine position. All the patients completed the brief pain inventory (BPI) assessment tool and quality of life questionnaire (QLQ-C30) from the European Organization for Research and Treatment of Cancer (EORTC) at the baseline, end of the treatment and 1, 2 and 3 months thereafter. The response to the treatment was assessed as the zero score (complete response) or two or more than two-point drop of the worst pain within the preceding 24 h (partial response) during the 3-month posttreatment. RESULTS All the pain intensity and interference scores, except the pain interference with the enjoyment of life score, significantly decreased. A total of 18 out of 23 patients (78%) achieved complete or partial response. The number of patients using pain relief medications decreased from 74% (n=17) at the baseline to 48% (n=11) 3 months later. Moreover, except for nausea and vomiting, appetite loss, diarrhea and financial impact problems, the patients' quality of life improved significantly in all the functional scales and symptoms within 3 months. CONCLUSION This study showed that using hyperthermia in combination with radiotherapy significantly ameliorated bone pain among the patients suffering from cancer with painful bony metastases.
Collapse
Affiliation(s)
- Tayebeh Ariyafar
- Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
| | - Seyed Rabie Mahdavi
- Department of Medical Physics, School of Medicine, Iran University of Medical Science, Tehran, Iran
| | - Ghazale Geraily
- Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
| | - Pedram Fadavi
- Radiation Oncology Department, Iran University of Medical Sciences, Tehran, Iran
| | - Bagher Farhood
- Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran
| | - Masoud Najafi
- Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Asieh Ashouri
- Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Leila Khalafi
- Department of Medical Physics, School of Medicine, Iran University of Medical Science, Tehran, Iran
| | - Alireza Shirazi
- Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
18
|
Mortazavizadeh MR, Ayoughi Y, Bashardoost N, Fadavi P. Low rates of symptomatic venous thromboembolism in patients with gastrointestinal cancer: an Iranian study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Pedram Fadavi
- Department of Radiation Oncology,Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran
| |
Collapse
|
19
|
Novin K, Hashemi Bahremani M, Mortazavi N, Ahmad A, Razaghi Z, Fadavi P. Blood neutrophil to lymphocyte ratio as a predictor of response to chemotherapy in head and neck cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e23078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Kambiz Novin
- Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran (Islamic Republic of)
| | - Mohammad Hashemi Bahremani
- Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran (Islamic Republic of)
| | - Nafiseh Mortazavi
- Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran (Islamic Republic of)
| | - Ameri Ahmad
- Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran
| | - Zahra Razaghi
- Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Pedram Fadavi
- Department of Radiation Oncology,Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran
| |
Collapse
|
20
|
Abstract
Small bowel cancer is one of the rarest cancers in the gastrointestinal tract. The diagnosis is usually late and most patients presented with the advanced stage. Because of this rarity, there is limited data when making decisions for treatment and biological behavior. Most forms of the cancer occur in the duodenum with surgery being the treatment of choice if the cancer is operable. Chemotherapy has an accepted role in duodenal cancer, with the best form being regimen, which yields the best result in combination with capecitabin and oxaliplatin. Our case patient was present with liver metastasis and a huge mass in her first duodenal region so we were required to use chemotherapy and radiotherapy. Like other duodenal cancers, the metastasis decreased her survival and she died about 13 months after diagnosis.
Collapse
Affiliation(s)
- Pedram Fadavi
- Department of Radiation Oncology, Hafte Tir Hospital, Iran University of Medical Science , Tehran, Iran
| | - Mahkameh Zare
- Department of Radiation Oncology, Hafte Tir Hospital, Iran University of Medical Science , Tehran, Iran
| |
Collapse
|
21
|
Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M, Khoie S, Gharehbagh EJ, Farahani S, Mohebbi A, Vasheghani M, Zare M, Nikoofar A, Mahdavi SRM. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol 2015; 32:200. [PMID: 26071124 DOI: 10.1007/s12032-015-0646-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Accepted: 05/22/2015] [Indexed: 11/25/2022]
Abstract
The aim of this study was to investigate the risk of sensorineural hearing loss (SNHL) and the relationship between SNHL and radiation dose to the cochlea and frequency range of hearing loss in patients with head and neck cancer. Pure tone audiometry at 250-12,000 Hz was performed on 29 patients diagnosed with head and neck tumours who were treated with 3-dimensional conformal radiation therapy and followed up for 6 months. Paired t test indicated that the mean air conduction threshold before and after radiotherapy was significantly different (paired t test, p < 0.001). SNHL was observed in 15 patients (51 %) according to CTCAE. SNHL increased to 77 % in patients who had received at least five concurrent cisplatin cycles. There was an increased risk of SNHL for ears receiving a mean dose of 5000 cGy compared to those receiving <5000 cGy. SNHL was more severe at higher frequencies of pure tone audiometry in patients with cisplatin-based chemoradiation. The ototoxicity effect of radiation and cisplatin must be considered in the treatment of head and neck tumours. Increasing the dose of cisplatin, radiation dose of cochlea and follow-up interval time may result in increasing severity and frequency of hearing loss incidences. However, characteristic of radiation-induced SNHL seems to be different from chemoradiation-induced SNHL.
Collapse
Affiliation(s)
- Susan Cheraghi
- Department of Medical Physics, School of Medicine, Iran University of Medical Science, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Feizy A, Moghimi M, Fadavi P, Talebipoor B, Mazdai G, Attarian S, Taheri H, Zamiri RE. The relationship between overexpression of HER2 with tumor grade and 3-years overall survival of gastric cancer patients referring to Valiasr Hospital of Zanjan. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e15050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Hadi Taheri
- Zanjan University of Medical Science, Zanjan, Iran
| | | |
Collapse
|
23
|
Aslian H, Sadeghi M, Mahdavi SR, Babapour Mofrad F, Astarakee M, Khaledi N, Fadavi P. Magnetic resonance imaging-based target volume delineation in radiation therapy treatment planning for brain tumors using localized region-based active contour. Int J Radiat Oncol Biol Phys 2013; 87:195-201. [PMID: 23920396 DOI: 10.1016/j.ijrobp.2013.04.049] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2013] [Revised: 04/09/2013] [Accepted: 04/25/2013] [Indexed: 11/18/2022]
Abstract
PURPOSE To evaluate the clinical application of a robust semiautomatic image segmentation method to determine the brain target volumes in radiation therapy treatment planning. METHODS AND MATERIALS A local robust region-based algorithm was used on MRI brain images to study the clinical target volume (CTV) of several patients. First, 3 oncologists delineated CTVs of 10 patients manually, and the process time for each patient was calculated. The averages of the oncologists' contours were evaluated and considered as reference contours. Then, to determine the CTV through the semiautomatic method, a fourth oncologist who was blind to all manual contours selected 4-8 points around the edema and defined the initial contour. The time to obtain the final contour was calculated again for each patient. Manual and semiautomatic segmentation were compared using 3 different metric criteria: Dice coefficient, Hausdorff distance, and mean absolute distance. A comparison also was performed between volumes obtained from semiautomatic and manual methods. RESULTS Manual delineation processing time of tumors for each patient was dependent on its size and complexity and had a mean (±SD) of 12.33 ± 2.47 minutes, whereas it was 3.254 ± 1.7507 minutes for the semiautomatic method. Means of Dice coefficient, Hausdorff distance, and mean absolute distance between manual contours were 0.84 ± 0.02, 2.05 ± 0.66 cm, and 0.78 ± 0.15 cm, and they were 0.82 ± 0.03, 1.91 ± 0.65 cm, and 0.7 ± 0.22 cm between manual and semiautomatic contours, respectively. Moreover, the mean volume ratio (=semiautomatic/manual) calculated for all samples was 0.87. CONCLUSIONS Given the deformability of this method, the results showed reasonable accuracy and similarity to the results of manual contouring by the oncologists. This study shows that the localized region-based algorithms can have great ability in determining the CTV and can be appropriate alternatives for manual approaches in brain cancer.
Collapse
Affiliation(s)
- Hossein Aslian
- Department of Medical Radiation, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | | | | | | | | | | | | |
Collapse
|
24
|
Kamal M, El-Khateeb N, Awad M, Zaghloul MS, Ahmed S, El-Beltagy M, Taha H, Refaat A, Abouelnaga S, Refaat A, Aggag M, Youssef A, Kamal M, Gharieb A, El-Beltagy M, Taha H, Ezzat S, Kamal M, Hassanain O, Abouelnaga S, Hussein H, Hosny H, Sabry M, Samir A, El-Beltagy M, Kamal M, Zaghloul MS, Abouelnaga S, Taha H, El Beltagy M, Atteya M, Moiyadi A, Shetty P, El-Shazly M, El Masry A, Quaddoumi I, El-Fiki M, Fadel S, Xiong H, Shao J, Li J, Xu Z, Ezziane-Guechi K, Atif ML, Bouzid K, Bezzaoucha A, Faranoush M, Mehrvar A, Asl AAH, Tashvighi M, Parsa RR, Fazeli MA, Sobuti B, Mehrvar N, Ali J, Zangooei R, Alebouyeh M, Vossough P, Perek D, Baginska BD, Drogosiewicz M, Polnik MP, Grajkowska W, Roszkowski M, Sobol G, Musiol K, Wachowiak J, Kazmierczak B, Pogorzelski JP, Mlynarski W, Szewczyk BZ, Wysocki M, Niedzielska E, Kowalczyk J, Slusarz HW, Balwierz W, Czepko EZ, Szolkiewicz A, Haddad P, Zali A, Tabatabaeefar M, Nikoofar A, Kharazi HH, Ghadyani M, Fadavi P, Mukhomorova L, Faranoush M, Nami MT, Botelho I, Pedrosa F, Qaddoumi I, Ribeiro R, Pedrosa A, Hazim A, Furtado G, Serra S, Procopio S, Pillai A, Mr B, Panikar D, Jarrar M, Alharbi M, Alharbi T, Alsudairy R, Alomari A, Aljamaan K, Alsultan A, Hnin TM, Khaing A, Tin HH, Ebeid E, El Haddad M, Mansour A, El Haddad A, Maza I, Vasquez L, Ordonez K, Paredes G, Yabar A, Ugarte E, Geronimo J. NEURO-ONCOLOGY IN DEVELOPING COUNTRIES. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Rasouli HA, Moghadam MM, Tabatabaiefar M, Taslimi F, Sheybani KM, Alidoosti A, Ameri A, Fadavi P, Aref S. Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer. Acta Med Iran 2012; 50:43-46. [PMID: 22267378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
The objective of this study was to determine and compare cystatin C changes before and after radiotherapy in patients with stomach cancer who were candidate for radiotherapy. This study was conducted as a prospective cohort one. Eighteen patients with definite diagnosis of stomach cancer under treatment by radiotherapy who presented to Radiotherapy-Oncology Center of Imam Hossein Hospital, Tehran-Iran, and the treatment in all cases was simultaneous chemoradiation with Xeloda were included. In all patients before radiotherapy and after radiotherapy serum creatinine (Cr) and cystatin C were measured simultaneously. Mean cystatin level before treatment (1.2 ± 0.4) was significantly lower than that of post-treatment (1.6 ± 0.36), (P=0.001). Serum Cr level before treatment was 1.15 ± 0.33 and after radiotherapy was 1.08 ± 0.24 and did not show significant difference. Glomerular filtration rate (GFR) of the patients before radiotherapy was -46.8 ± 21.0 and after radiotherapy was 43.8 ± 15.8 that did not have significant difference (P=0.146) and also blood urea nitrogen (BUN) before radiotherapy was 20.72 ± 3.7 and 20 ± 6.38 after radiotherapy that did not have significant difference (P=0.6). Comparison of the cystatin C difference with total radiation dose of the kidneys that are put in three dose groups in radiotherapy field had association that in dose of less that 18 gray (Gy) the cystatin C change showed significant and positive association (P=0.027; r=0.52) and about 18-24 Gy the cystatin C difference showed significant and negative association (P=0.023, r=-0.53). It seems that for evaluating the renal function, serum cystatin C measurement is preferable than serum Cr. level.
Collapse
Affiliation(s)
- Hooshang Amir Rasouli
- Department of Radiotherapy-Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
There is convincing evidence for a genetic component in susceptibility to tuberculosis (TB) in humans. Attempts to link susceptibility to TB to human leukocyte antigen (HLA) phenotype have produced conflicting data. The purpose of this study was to determine whether HLA phenotype is associated with clinical TB. We compared the frequencies of HLA alleles in 44 Iranian sputum smear positive pulmonary TB patients with allele frequencies of 108 healthy adults. HLA typing was performed by lymphocytotoxicity assay. The frequencies of HLA-B17 and -DR14 were higher in TB patients and the frequencies of HLA-A26 and -B27 were higher in healthy controls (p value < 0.05, corrected p value [pc] >0.05). Our findings suggest that these alleles are associated (either positively or negatively) with pulmonary TB in an Iranian population. However, considering corrected p value, our data are not conclusive and should be considered preliminary.
Collapse
|